Pharmaceutical major Dr Reddy’s has reported 22 percent jump in profit before tax for fourth quarter and 10 percent growth in revenue.

Gilead Sciences CEO Daniel O’Day said on Friday that the company is focused on experimental coronavirus drug that is affordable and widely accessible.

Market analyst Ashwani Gujral is bullish for the day with five BUY Calls for stocks.

ABBOTT India is a good long term investment for Indian investors as per Nirali Shah, SAMCO Research.

Lupin and Aurobindo Pharma have been recommended for hold by research house Prabhudas Lilladher. Target price for Aurobindo Pharma has been suggested Rs 511.

Panacea Biotec has reported lower quarterly loss at Rs 28 crore compared to the same period last year. The company has managed to reduce its losses and increase its sales revenue to Rs 125 crore compared to Rs 99 crore for the same period last year.

The company also informed that it has received United States Food and Drug Administration (USFDA) approval for Oncology Parenteral Formulations.

Talking about the results, Panacea Biotec MD Rajesh Jain said, "The company's remediation measures have now started paying off. The company has registered impressive financial performance during the quarter ended June 30, 2019 with 28 per cent topline growth and earning positive earnings before interest, taxes, depreciation and amortization (EBITDA) of Rs 26.9 crore."